MCMCB Pro
J9381

J9381Injection, teplizumab-mzwv, 5 mcg

HCPCSActiveBETOS O1E

J9381 is a HCPCS Level II code for injection, teplizumab-mzwv, 5 mcg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits — units per day

The most units of J9381 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
800 units
MAI 3 — Date of Service Edit: Clinical · CMS Policy
outpatient
800 units
MAI 3 — Date of Service Edit: Clinical · CMS Policy

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.

The CMS record for J9381

Long descriptor
Injection, teplizumab-mzwv, 5 mcg

The official wording. This is what the code means.

Short descriptor
Inj teplizumab mzwv 5 mcg

CMS's 28-character form, which is what shows up on a remittance advice.

Added
July 1, 2023

When CMS introduced the code.

BETOS
O1E

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
51 — Other

Drugs.

Codes adjacent to J9381

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9381 is not quite right, the correct code is very often within a few positions of it.

  • J9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
  • J9359Injection, loncastuximab tesirine-lpyl, 0.075 mg
  • J9360Injection, vinblastine sulfate, 1 mg
  • J9361Injection, efbemalenograstim alfa-vuxw, 0.5 mg
  • J9370Vincristine sulfate, 1 mg
  • J9371Injection, vincristine sulfate liposome, 1 mgterminated
  • J9376Injection, pozelimab-bbfg, 1 mg
  • J9380Injection, teclistamab-cqyv, 0.5 mg
  • J9382Injection, zenocutuzumab-zbco, 1 mg
  • J9390Injection, vinorelbine tartrate, 10 mg
  • J9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
  • J9394Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg
  • J9395Injection, fulvestrant, 25 mg
  • J9400Injection, ziv-aflibercept, 1 mg
  • J9600Injection, porfimer sodium, 75 mg
  • J9601Injection, linvoseltamab-gcpt, 1 mg

Questions about J9381

What is HCPCS code J9381?

J9381 is a HCPCS Level II code for injection, teplizumab-mzwv, 5 mcg. It sits in the Drugs Administered Other Than Oral Method section.

Does Medicare cover J9381?

The CMS HCPCS file marks J9381 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

How is J9381 paid under the physician fee schedule?

J9381 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

HCPCS Level II2026Q3-Jul· effective July 1, 2026